Evidence map›Paper›PMID 37231237›Full record

ArticleNeurocritical care2023

Effect of an Albumin Infusion Treatment Protocol on Delayed Cerebral Ischemia and Relevant Outcomes in Patients with Subarachnoid Hemorrhage.

Andrés Gempeler, Leidy Gaviria, Alejandra Ortiz, Natalia Jaramillo, Luis Beltrán, Sara Escobar, Martín Rondón, Diego Rosselli, Jorge E Martinez-Buitrago, Jorge H Mejía-Mantilla

Abstract read
PubMed Publisher
In one paragraph

Article in Neurocritical care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Andrés GempelerCentro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia. andres.gempeler@fvl.org.co.ORCID http://orcid.org/0000-0001-9217-9500
Leidy GaviriaCentro de Investigaciones Clínicas, Fundación Valle del Lili, Cali, Colombia.
Alejandra OrtizFacultad de ciencias de la salud, Universidad Icesi, Cali, Colombia.
Natalia JaramilloFacultad de ciencias de la salud, Universidad Icesi, Cali, Colombia.
Luis BeltránFundación Valle del Lili, Cali, Colombia.
Sara EscobarFundación Valle del Lili, Cali, Colombia.
Martín RondónDepartment of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Cali, Colombia.
Diego RosselliDepartment of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Cali, Colombia.
Jorge E Martinez-BuitragoDepartment of Intensive Care Medicine, Fundación Valle del Lili, Cali, Colombia.
Jorge H Mejía-MantillaFacultad de ciencias de la salud, Universidad Icesi, Cali, Colombia.
Fundación Valle del Lili · COPontificia Universidad Javeriana · COIcesi University · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn institutional management protocol for patients with subarachnoid hemorrhage (SAH) based on initial cardiac assessment, permissiveness of negative fluid balances, and use of a continuous albumin infusion as the main fluid therapy for the first 5 days of the intensive care unit (ICU) stay was implemented at our hospital in 2014. It aimed at achieving and maintaining euvolemia and hemodynamic stability to prevent ischemic events and complications in the ICU by reducing periods of hypovolemia or hemodynamic instability. This study aimed at assessing the effect of the implemented management protocol on the incidence of delayed cerebral ischemia (DCI), mortality, and other relevant outcomes in patients with SAH during ICU stay.

methodsWe conducted a quasi-experimental study with historical controls based on electronic medical records of adults with SAH admitted to the ICU at a tertiary care university hospital in Cali, Colombia. The patients treated between 2011 and 2014 were the control group, and those treated between 2014 and 2018 were the intervention group. We collected baseline clinical characteristics, cointerventions, occurrence of DCI, vital status after 6 months, neurological status after 6 months, hydroelectrolytic imbalances, and other SAH complication. Multivariable and sensitivity analyses that controlled for confounding and considered the presence of competing risks were used to adequately estimate the effects of the management protocol. The study was approved by our institutional ethics review board before study start.

resultsOne hundred eighty-nine patients were included for analysis. The management protocol was associated with a reduced incidence of DCI (hazard ratio 0.52 [95% confidence interval 0.33-0.83] from multivariable subdistribution hazards model) and hyponatremia (relative risk 0.55 [95% confidence interval 0.37-0.80]). The management protocol was not associated with higher hospital or long-term mortality, nor with a higher occurrence of other unfavorable outcomes (pulmonary edema, rebleeding, hydrocephalus, hypernatremia, pneumonia). The intervention group also had lower daily and cumulative administered fluids compared with historic controls (p < 0.0001).

conclusionsA management protocol based on hemodynamically oriented fluid therapy in combination with a continuous albumin infusion as the main fluid during the first 5 days of the ICU stay appears beneficial for patients with SAH because it was associated with reduced incidence of DCI and hyponatremia. Proposed mechanisms include improved hemodynamic stability that allows euvolemia and reduces the risk of ischemia, among others.

Indexed as

Brain IschemiaHyponatremiaSubarachnoid HemorrhageAdultCerebral InfarctionClinical ProtocolsHumansAlbuminsAneurysmColloidsFluid therapyIntracranial aneurysmRupturedSubarachnoid hemorrhage

Identifiers

PMID37231237
OpenAlexW4378190927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.